Carnegie Capital Asset Management, LLC Gilead Sciences, Inc. Transaction History
Carnegie Capital Asset Management, LLC
- $3.34 Billion
- Q3 2024
A detailed history of Carnegie Capital Asset Management, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Carnegie Capital Asset Management, LLC holds 32,548 shares of GILD stock, worth $2.94 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
32,548
Previous 31,375
3.74%
Holding current value
$2.94 Million
Previous $2.15 Million
26.77%
% of portfolio
0.08%
Previous 0.07%
Shares
30 transactions
Others Institutions Holding GILD
# of Institutions
1,923Shares Held
994MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$10.9 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.4 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$6.9 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.57 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.43 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $113B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...